Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390246 | 0.91 | MEN1 (0.41) | LIPEMEN1KMT2AEPHX2PKM | |
| SCHEMBL4388886 | 0.91 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2AEPHX2 | |
| SCHEMBL4384892 | 0.88 | LIPE (0.41) | LIPEALDH1A1SMN1; SMN2SCN9AMEN1 | |
| SCHEMBL4386218 | 0.88 | LIPE (0.45) | LIPEALDH1A1SMN1; SMN2SCN9AMEN1 | |
| SCHEMBL4377720 | 0.88 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2ACYP2C9 | |
| SCHEMBL4383840 | 0.88 | MEN1 (0.46) | ALDH1A1SMN1; SMN2MEN1KMT2AEPHX2 | |
| SCHEMBL4380640 | 0.87 | LIPE (0.40) | LIPEALDH1A1SMN1; SMN2SCN9AMEN1 | |
| SCHEMBL13589005 | 0.85 | MEN1 (0.39) | LIPEALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4381887 | 0.85 | HDAC3 (0.42) | LIPESCN9AMEN1KMT2AEPHX2 | |
| SCHEMBL4380318 | 0.85 | MEN1 (0.39) | LIPESMN1; SMN2MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LIPE 2501/4885ALDH1A1 2105/4885SMN1; SMN2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.